168 related articles for article (PubMed ID: 12713628)
41. Heterogeneous nuclear ribonucleoprotein B1 expression in malignant mesothelioma.
Hiraki A; Murakami T; Aoe K; Sueoka E; Sueoka N; Taguchi K; Kamei T; Sugi K; Ueoka H; Kishimoto T
Cancer Sci; 2006 Nov; 97(11):1175-81. PubMed ID: 16939492
[TBL] [Abstract][Full Text] [Related]
42. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
43. Unusual features of malignant pleural mesothelioma metastatic to the mediastinal lymph nodes.
Wagner D; Bourne PA; Yang Q; Goldman BI; Lewis JS; Xu H
Appl Immunohistochem Mol Morphol; 2008 May; 16(3):301-7. PubMed ID: 18301236
[TBL] [Abstract][Full Text] [Related]
44. Benign and malignant mesothelial lesions of the pleura: quantitative study.
Ranaldi R; Marinelli F; Barbatelli G; Mariuzzi G; Marzocchi F; Mancini AM; Pisani E; Ansuini G; Ricci M
Appl Pathol; 1986; 4(1-2):55-64. PubMed ID: 3580194
[TBL] [Abstract][Full Text] [Related]
45. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
[TBL] [Abstract][Full Text] [Related]
46. [Cell marker for the differential diagnosis of malignant mesotheliomas].
Hastka J; Pfiester P
Pathologe; 1988 Jul; 9(4):245-7. PubMed ID: 2463617
[No Abstract] [Full Text] [Related]
47. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
Johansson L; Lindén CJ
Chest; 1996 Jan; 109(1):109-14. PubMed ID: 8549169
[TBL] [Abstract][Full Text] [Related]
48. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
49. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
50. Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies.
Allen TC
Arch Pathol Lab Med; 2005 Nov; 129(11):1415-20. PubMed ID: 16253022
[TBL] [Abstract][Full Text] [Related]
51. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
52. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens.
Cagle PT; Brown RW; Lebovitz RM
Hum Pathol; 1994 May; 25(5):443-8. PubMed ID: 8200637
[TBL] [Abstract][Full Text] [Related]
53. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259
[TBL] [Abstract][Full Text] [Related]
54. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
Epstein JI; Budin RE
Hum Pathol; 1986 May; 17(5):514-9. PubMed ID: 2422109
[TBL] [Abstract][Full Text] [Related]
55. Pleural biopsy in the diagnosis of malignant mesothelioma.
Herbert A; Gallagher PJ
Thorax; 1982 Nov; 37(11):816-21. PubMed ID: 7163999
[TBL] [Abstract][Full Text] [Related]
56. Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach.
Kradin RL; Mark EJ
Semin Diagn Pathol; 2006 Feb; 23(1):4-14. PubMed ID: 17044190
[TBL] [Abstract][Full Text] [Related]
57. Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype.
Beer TW; Buchanan R; Matthews AW; Stradling R; Pullinger N; Pethybridge RJ
Hum Pathol; 1998 Mar; 29(3):246-51. PubMed ID: 9496827
[TBL] [Abstract][Full Text] [Related]
58. Cadherins, catenins and APC in pleural malignant mesothelioma.
Abutaily AS; Collins JE; Roche WR
J Pathol; 2003 Nov; 201(3):355-62. PubMed ID: 14595746
[TBL] [Abstract][Full Text] [Related]
59. [Pleural mesothelioma: morphology, histochemistry, difficulties in diagnosis and nosologic problems (author's transl)].
Abelanet R; Jagueux M; Fondimare A; Roujeau J
Rev Fr Mal Respir; 1979; 7(3):243-64. PubMed ID: 91185
[TBL] [Abstract][Full Text] [Related]
60. Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases.
Galateau-Sallé F; Attanoos R; Gibbs AR; Burke L; Astoul P; Rolland P; Ilg AG; Pairon JC; Brochard P; Begueret H; Vignaud JM; Kerr K; Launoy G; Imbernon E; Goldberg M
Am J Surg Pathol; 2007 May; 31(5):711-6. PubMed ID: 17460454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
